LOS ANGELES, May 25, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced that Patrick Hwu, M.D., and Mario Sznol, M.D., have joined the Company's recently formed Scientific and Medical Advisory Board (SMAB).
Dr. Hwu is currently on the faculty of the University of Texas MD Anderson Cancer Center in Houston, and serves as chairman of the Center's Department of Melanoma Medical Oncology, Division of Cancer Medicine.
Dr. Sznol is currently on the faculty of Yale University School of Medicine, and is Professor of Medicine (Medical Oncology), and also serves as Vice-Chief Medical Oncology and Co-Director of the Yale Cancer Center Melanoma Program.
"We are pleased that Drs. Hwu and Sznol have joined our new Scientific and Medical Advisory Board, and look forward to their contribution in helping to guide our autologous cell therapy program," said Anthony J. Cataldo, President and Chief Executive Officer.
Drs. Hwu and Sznol join other leading oncologists and cancer researchers on the prestigious Genesis Biopharma SMAB who include: Cassian Yee, M.D., Professor of Medicine at the University of Washington's Fred Hutchinson Cancer Research Center; James Mule, Ph.D., and Jeffrey Weber, M.D., Ph.D., of the H. Lee Moffitt Cancer Center & Research Institute; David DiGiusto, Ph.D., of the City of Hope; and Daniel Powell, Ph.D., from the University of Pennsylvania School of Medicine.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.
The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
|SOURCE Genesis Biopharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved